ORAL

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Retrieved on: 
목요일, 5월 9, 2024
Disorder, Common, Risk, GC, Overweight, Trial of the century, Adrenocorticotropic hormone, Hyperlipidemia, Associate, Deficit spending, Hydrocortisone, Neurocrine Biosciences, White matter, Food, Oklahoma State University–Stillwater, Cognition, Psychology, Testosterone, Male, Literature, Brain, DSM-IV codes, A4, SAN, GCS, CAH, Acne, Safety, Glucocorticoid, Research, Depression, Congenital adrenal hyperplasia, Osteopenia, Anxiety, Division, Hirsutism, Androstenedione, Psychiatry, Psychosis, Hypertension, Metabolism, Poster, Pharmaceutical industry

The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.

Key Points: 
  • The CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
  • These new data were presented at oral presentations and poster sessions at the American Association of Clinical Endocrinology 2024 Annual Meeting in New Orleans.
  • Despite supraphysiologic GC dosing, levels of adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione (A4) were elevated at baseline, with levels of testosterone (females) and A4/testosterone (males) also elevated.
  • The data from both studies supported two New Drug Applications submitted to the U.S. Food and Drug Administration in April 2024.

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on: 
목요일, 5월 9, 2024
FDA, Research, UCL Business, Weight loss, IND, Oxyntomodulin, Visual acuity, RIX, Oral medicine, American Academy, Brain, STN, Facial muscles, Technology transfer, Janssen Pharmaceuticals, Appetite, BLA, MHRA, Messenger, Subthalamic nucleus, Safety, Diabetes, Insurance, RNA, AAOM, AAV, Dopamine, Obesity, DNA, Autoimmune disease, Motor cortex, Treatment, Pros, GMP, GIP, Clinical trial, File, PSMA, Sale, Radiation, Neurodegenerative disease, DSM-IV codes, Saliva, Health care, Xerostomia, Patient, Riboswitch, Gene, Peptide, Head, PYY, Pharmaceutical industry

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
  • As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
  • The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
  • Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

Retrieved on: 
월요일, 5월 6, 2024
FDA, DRSS, PDR, Safety, Risk, Food, Diabetic retinopathy, Research, OCUP, Binocular, Retina, Patient, Eye, Annual general meeting, ARVO, DR, Pharmaceutical industry

ZETA-1 was a Phase 2, randomized, double-masked trial evaluating the efficacy and safety of oral APX3330 compared to placebo in 103 participants with DR completed in January 2023.

Key Points: 
  • ZETA-1 was a Phase 2, randomized, double-masked trial evaluating the efficacy and safety of oral APX3330 compared to placebo in 103 participants with DR completed in January 2023.
  • This 17-step person-level scale accounts for the DRSS scores of the two eyes and then anchors the step to the worse eye.
  • Fewer participants in the APX3330 group developed proliferative diabetic retinopathy (PDR) by week 24 compared to the placebo group (11% vs 26% respectively; p=0.13).
  • APX3330 showed favorable safety and tolerability, with similar ocular adverse events between APX3330 and placebo groups.

$175+ Bn Pharmaceutical Packaging Markets - Global Forecast to 2031: Growth Driven by Growing Counterfeiting, Implementation of Regulations, and Contract Packaging Trends - ResearchAndMarkets.com

Retrieved on: 
화요일, 5월 7, 2024
Packaging, Pharmaceutical, Health, Manufacturing, Vaccination, PP, Glass, Safety, Route of administration, PET, Plastic, Paper, Conditional sentence, Metal, Syringe, Ageing, Temperature, Government, Ampoule, Growth, Polyvinyl chloride, Prevalence

The global pharmaceutical packaging market is projected to reach $176.54 billion by 2031 at a CAGR of 7.6% from 2024 to 2031.

Key Points: 
  • The global pharmaceutical packaging market is projected to reach $176.54 billion by 2031 at a CAGR of 7.6% from 2024 to 2031.
  • However, increasing instances of counterfeit packaging, increasing waste generation due to single-use packaging, and concerns over certain materials leaching into pharmaceutical preparations restrain the growth of this market.
  • North America is expected to account for the largest share of the pharmaceutical packaging market.
  • In the region in 2024, the U.S. is expected to account for the largest share of the pharmaceutical packaging market in North America.

THE CALIFORNIA FIRE FOUNDATION HELPS CALIFORNIANS PREPARE FOR WILDFIRES, SUPPORTS FIRE VICTIMS, AND HONORS FIREFIGHTERS FOR MAY WILDFIRE PREPAREDNESS MONTH

Retrieved on: 
월요일, 5월 6, 2024
Firefighter, Social media, Friends, The Memorial

SACRAMENTO, Calif., May 6, 2024 /PRNewswire/ -- To mark May Wildfire Preparedness Month, the California Fire Foundation (www.cafirefoundation.org), the California-based non-profit that assists families of fallen firefighters, firefighters, and the communities they protect, is helping Californians prepare for fire season, supporting fire victims, and honoring fallen firefighters across California.  Governor Gavin Newsom also just issued a proclamation declaring May 5–11, 2024, as "Wildfire Preparedness Week" in the State of California.

Key Points: 
  • Governor Gavin Newsom Declares May 5–11, 2024, as "Wildfire Preparedness Week"
    SACRAMENTO, Calif., May 6, 2024 /PRNewswire/ -- To mark May Wildfire Preparedness Month , the California Fire Foundation ( www.cafirefoundation.org ), the California-based non-profit that assists families of fallen firefighters, firefighters, and the communities they protect, is helping Californians prepare for fire season, supporting fire victims, and honoring fallen firefighters across California.
  • Governor Gavin Newsom also just issued a proclamation declaring May 5–11, 2024, as "Wildfire Preparedness Week" in the State of California.
  • "Our typical wildfire season used to be July to October, but Californians need to stay prepared year-round," said Brian Rice, Chair of the California Fire Foundation and President of California Professional Firefighters.
  • "Community preparedness and raising funds are critical to our mission to support both residents and our firefighters and their families."

Pharmaceutical Packaging Market to Be Worth $176.54 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
금요일, 5월 3, 2024
PFS, United Nations, Polyvinyl chloride, Investment, PP, Ampoule, PVC, Polymer, Medicine, Paper, AptarGroup, Gas, Sachet, Blister, Drug discovery, PET, Inhaler, Catalent, Drug packaging, Cellulose, Tablet, Corning Inc., Regulation (European Union), Conditional sentence, Research, Transport, Carbon, QR, Shield, Government, WestRock, Polyethylene, Capsule, Syringe, Glass, Route of administration, Environment, United, Amcor, Growth, Fine chemical

Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.

Key Points: 
  • Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.
  • Key findings in the pharmaceutical packaging market report:
    Among all the materials studied in this report, in 2024, the polymer segment is expected to account for the largest share of 43% of the pharmaceutical packaging market.
  • Among all the packaging types studied in this report, in 2024, the primary packaging segment is expected to account for the largest share of 72% the pharmaceutical packaging market.
  • However, Asia-Pacific pharmaceutical packaging market is expected to growth with the highest CAGR of 8.5% over the forecast period.

Pharmaceutical Packaging Market to Be Worth $176.54 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
금요일, 5월 3, 2024
PFS, United Nations, Polyvinyl chloride, Investment, PP, Ampoule, PVC, Polymer, Medicine, Paper, AptarGroup, Gas, Sachet, Blister, Drug discovery, PET, Inhaler, Catalent, Drug packaging, Cellulose, Tablet, Corning Inc., Regulation (European Union), Conditional sentence, Research, Transport, Carbon, QR, Shield, Government, WestRock, Polyethylene, Capsule, Syringe, Glass, Route of administration, Environment, United, Amcor, Growth, Fine chemical

Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.

Key Points: 
  • Pharmaceutical companies are increasingly focusing on sustainable pharmaceutical packaging in order to cut waste and reduce their carbon footprint.
  • Key findings in the pharmaceutical packaging market report:
    Among all the materials studied in this report, in 2024, the polymer segment is expected to account for the largest share of 43% of the pharmaceutical packaging market.
  • Among all the packaging types studied in this report, in 2024, the primary packaging segment is expected to account for the largest share of 72% the pharmaceutical packaging market.
  • However, Asia-Pacific pharmaceutical packaging market is expected to growth with the highest CAGR of 8.5% over the forecast period.

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

Retrieved on: 
목요일, 4월 25, 2024
Cancer, Abstract, ASCO, Patient, Society, Oncology nursing, Poster, Annual general meeting, Cervical cancer, Pharmaceutical industry

SHANGHAI and HONG KONG, April 25, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four abstracts (including one oral presentation and three poster presentations) at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL, the United States.

Key Points: 
  • SHANGHAI and HONG KONG, April 25, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four abstracts (including one oral presentation and three poster presentations) at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL, the United States.
  • Details of the Oral Presentation:
    Title: A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort
    Session: Clinical Science Symposium – Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum
    2:15 AM - 3:45 AM, June 2, 2024 (Beijing Time)
    Details of the Poster Presentations:
    Title: A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)

Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
금요일, 4월 12, 2024
Real-World Evidence, Continuity, American Academy, University, FAAN, Parkinson's disease, Randomness, State university system, Abstract, Research, Spirometry, MDT, ALS, Movement disorder, AAN, Disease, MTPA, Control, Data mart, Boundless, Annual general meeting, ISR, University of Cincinnati, Session 9, Knowledge, Pharmaceutical industry

JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.

Key Points: 
  • JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.
  • The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
  • Data from the BouNDless subgroup analysis will be presented orally during a Scientific Platform Session at the meeting.
  • ; State University of New York Upstate Medical University)
    Poster Session 6 (#11-013): 8:00 – 9:00 a.m. MDT, April 16

Recommendations for Head and Neck Cancer Awareness Month from the American Board of Oral and Maxillofacial Surgery

Retrieved on: 
목요일, 4월 11, 2024
Education, Throat, Sore throat, Patient, Cancer, CAQ, Mouth, Woman, Certification, Oral cancer, Risk, Neck, Head and neck cancer, Nose, Tobacco, Love, DMD, DDS, FACS, EDM, Oral and maxillofacial surgery, HPV, Head, Reconstructive surgery, Quality of life, Dentistry

CHICAGO, April 11, 2024 /PRNewswire/ -- The Executive Board and Diplomates of the American Board of Oral and Maxillofacial Surgery (ABOMS) recognize Head and Neck Cancer Awareness Month in April. Many ABOMS Diplomates are experts in head and neck cancer, which account for about 4 percent of cancer cases in the United States. They see this month as an opportunity to educate the public.

Key Points: 
  • To promote public awareness of head and neck cancer, board-certified oral and maxillofacial surgeons share facts and tips
    CHICAGO, April 11, 2024 /PRNewswire/ -- The Executive Board and Diplomates of the American Board of Oral and Maxillofacial Surgery (ABOMS) recognize Head and Neck Cancer Awareness Month in April.
  • Many ABOMS Diplomates are experts in head and neck cancer, which account for about 4 percent of cancer cases in the United States.
  • The American Board of Oral and Maxillofacial Surgery (ABOMS) certifies oral and maxillofacial surgeons who have proven their qualifications and expertise through education, training, and a thorough examination process.
  • Patients looking for a highly qualified oral and maxillofacial surgeon for their oncology team should look for this kind of specialized training and certification.